Download presentation
Presentation is loading. Please wait.
Published byTheodora Hodges Modified over 5 years ago
1
Persistent N2 disease after neoadjuvant chemotherapy for non–small-cell lung cancer
Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W. Onaitis, MD, Mark F. Berry, MD, Thomas A. D’Amico, MD, Chris R. Kelsey, MD The Journal of Thoracic and Cardiovascular Surgery Volume 142, Issue 5, Pages (November 2011) DOI: /j.jtcvs Copyright © Terms and Conditions
2
Figure 1 Outline of patients and treatment administered after neoadjuvant chemotherapy. The Journal of Thoracic and Cardiovascular Surgery , DOI: ( /j.jtcvs ) Copyright © Terms and Conditions
3
Figure 2 Kaplan-Meier curve demonstrating overall survival (OS), disease-free survival, and local control for entire cohort of patients with persistent N2 disease after neoadjuvant chemotherapy. The Journal of Thoracic and Cardiovascular Surgery , DOI: ( /j.jtcvs ) Copyright © Terms and Conditions
4
Figure 3 Kaplan-Meier curve demonstrating overall survival (OS) for patients with persistent N2 disease undergoing resection versus nonoperative treatment. The Journal of Thoracic and Cardiovascular Surgery , DOI: ( /j.jtcvs ) Copyright © Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.